12月19日，仙琚制药涨0.99%，成交额7938.51万元。两融数据显示，当日仙琚制药获融资买入额568.68 万元，融资偿还1240.07万元，融资净买入-671.39万元。截至12月19日，仙琚制药融资融券余额合计 4.94亿元。 融资方面，仙琚制药当日融资买入568.68万元。当前融资余额4.92亿元，占流通市值的5.41%，融资余 额超过近一年60%分位水平，处于较高位。 融券方面，仙琚制药12月19日融券偿还3800.00股，融券卖出300.00股，按当日收盘价计算，卖出金额 2757.00元；融券余量22.53万股，融券余额207.05万元，超过近一年90%分位水平，处于高位。 责任编辑：小浪快报 资料显示，浙江仙琚制药股份有限公司位于浙江省仙居县福应街道现代工业集聚区丰溪西路15号，成立 日期2000年6月26日，上市日期2010年1月12日，公司主营业务涉及甾体原料药和制剂的研制、生产与销 售。主营业务收入构成为：皮质激素63.39%，妇科及计生用药20.69%，其他9.21%，麻醉及肌松用药 6.71%。 截至11月30日，仙琚制药股东户数5.00万，较上期减少1.96%；人均流通股196 ...

Core Viewpoint - Xianju Pharmaceutical's stock has shown a mixed performance in recent trading, with a slight increase in price and notable changes in trading volume and shareholder structure [1][2]. Group 1: Stock Performance - On November 11, Xianju Pharmaceutical's stock rose by 2.06%, reaching 9.92 CNY per share, with a trading volume of 213 million CNY and a turnover rate of 2.20%, resulting in a total market capitalization of 9.813 billion CNY [1]. - Year-to-date, the stock price has increased by 3.98%, with a 4.86% rise over the last five trading days, a 3.55% increase over the last 20 days, but a decline of 6.42% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Xianju Pharmaceutical reported a revenue of 2.826 billion CNY, a year-on-year decrease of 12.71%, and a net profit attributable to shareholders of 407 million CNY, down 23.29% year-on-year [2]. - Cumulatively, the company has distributed 2.031 billion CNY in dividends since its A-share listing, with 989 million CNY distributed over the last three years [3]. Group 3: Shareholder Structure - As of September 30, 2025, the number of shareholders for Xianju Pharmaceutical was 49,600, a decrease of 0.82% from the previous period, with an average of 19,854 circulating shares per shareholder, an increase of 0.83% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the seventh largest, holding 8.126 million shares as a new shareholder, while the Southern CSI 1000 ETF is the eighth largest, holding 7.238 million shares, a decrease of 97,000 shares from the previous period [3]. Group 4: Business Overview - Xianju Pharmaceutical, established on June 26, 2000, and listed on January 12, 2010, specializes in the research, production, and sales of steroid raw materials and formulations [1]. - The company's main business revenue composition includes corticosteroids (63.39%), gynecological and family planning medications (20.69%), other products (9.21%), and anesthetics and muscle relaxants (6.71%) [1].

Core Viewpoint - Xianju Pharmaceutical experienced a slight decline in stock price and notable trading activity, indicating potential investor concerns and market dynamics [1][2]. Financing Summary - On October 16, Xianju Pharmaceutical had a financing buy-in amount of 13.11 million yuan, with a net financing outflow of 2.94 million yuan, reflecting a high financing balance of 567 million yuan, which constitutes 5.81% of its market capitalization [1]. - The financing balance is above the 80th percentile of the past year, indicating a high level of investor engagement [1]. - The company also reported a securities lending situation with a total of 15.31 million shares available for lending, with a balance of 1.51 million yuan, also above the 80th percentile of the past year [1]. Business Performance - For the first half of 2025, Xianju Pharmaceutical reported a revenue of 1.869 billion yuan, a year-on-year decrease of 12.56%, and a net profit attributable to shareholders of 308 million yuan, down 9.26% year-on-year [2]. - The company's main revenue sources include corticosteroids (63.39%), gynecological and contraceptive drugs (20.69%), other medications (9.21%), and anesthetics and muscle relaxants (6.71%) [1]. Shareholder Information - As of September 30, the number of shareholders for Xianju Pharmaceutical stood at 50,000, with no change from the previous period [2]. - The cumulative cash dividends paid by the company since its A-share listing amount to 2.031 billion yuan, with 989 million yuan distributed over the last three years [3]. - Notably, the Southern CSI 1000 ETF is among the top ten circulating shareholders, increasing its holdings by 1.4094 million shares [3].

Core Insights - Xianju Pharmaceutical experienced a decline of 1.07% in stock price on September 17, with a trading volume of 172 million yuan [1] - The company reported a financing net buy of -6.08 million yuan on the same day, indicating a higher level of financing repayment compared to new purchases [1][2] - As of September 8, the number of shareholders increased by 8.70% to 50,000, while the average circulating shares per person decreased by 8.00% to 19,691 shares [2] Financing and Margin Trading - On September 17, Xianju Pharmaceutical had a financing buy amount of 18.39 million yuan, with a total financing balance of 639 million yuan, representing 6.36% of its market capitalization [1] - The financing balance is above the 90th percentile of the past year, indicating a high level of financing activity [1] - The company had no shares repaid in margin trading on September 17, with 300 shares sold short, amounting to 3,048 yuan [1] Financial Performance - For the first half of 2025, Xianju Pharmaceutical reported a revenue of 1.869 billion yuan, a year-on-year decrease of 12.56%, and a net profit attributable to shareholders of 308 million yuan, down 9.26% year-on-year [2] - Cumulatively, the company has distributed 1.932 billion yuan in dividends since its A-share listing, with 890 million yuan distributed in the last three years [3] Shareholder Composition - As of June 30, 2025, the top ten circulating shareholders included the Southern CSI 1000 ETF, which increased its holdings by 1.4094 million shares to 7.3351 million shares [3] - Hong Kong Central Clearing Limited and Xingquan He Feng Mixed Fund exited the list of top ten circulating shareholders [3]